BSL2 Expertise and Capacity

/BSL2 Expertise and Capacity
BSL2 Expertise and Capacity 2017-07-04T10:23:04+00:00

In 1796, the first vaccine was discovered. Few medical advances have made as large an impact on world health as vaccines. As new infectious diseases emerge, as old ones grow resistant, and as our understanding of human immune response increases, researchers are developing novel vaccines, gene therapies, creative delivery tools, and innovative approaches to treating infectious and genetic diseases. The preclinical realm is especially important to identify and advance the most promising drug or device candidates that could save lives.

MPI Research is dedicated to assisting developers in producing vaccines and gene and cell therapies to fight against diseases. In many cases, Biosafety Level 2 (BSL2) compliant laboratory and vivarium space is required for these drug development projects. MPI Research is compliant with all of the standards set by the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH). Also, MPI Research has an Institutional Biosafety Committee (IBC) where we have an active Biosafety Officer (BSO) in an effort to adhere to all IBC policies and procedures.

  • Biosafety level (BSL) 2 laboratory and vivarium space
    • Restricted vivarium/laboratory access during studies
  • Full AAALAC accreditation
  • GLP compliant
  • 18-plus rooms available
  • BSL2 barrier facilities, HEPAfiltration, and microisolator caging systems
  • Nonhuman primates (NHP)
  • Canines
  • Chinchillas
  • Rodents
  • Rabbits
  • Ferrets
  • Bacterial peritonitis/septicemia (mouse; MRSA, Streptococcus pneumoniae)
  • Acute bacterial otitis media (chinchilla; Haemophilus influenzae)
  • Otitis externa (rabbit; Pseudomonas aeruginosae)
  • Vaccine safety studies (rabbit, rodent, ferret, canine, NHP)
  • Gene and cell therapy studies (rodent, rabbit, dog, NHP)
  • Behavioral and functional assessments
  • Angiogenesis
  • Allodynia
  • Ocular morphology (OCT, fundus imaging)
  • Functional ocular assessment (ERG)
  • Immunofluorescence assays
  • High-resolution gel molecular imaging
  • Superior surgical, advanced molecular imaging (PET/CT and nanoSPECT/CT), and analytical capabilities
  • Targeted surgical delivery including
    • Intraocular
      • Intravitreal, subretinal, intracameral, subconjunctival/tenon
    • Intracranial
    • Intraspinal
    • Intrathecal
    • Intracoronary
    • Myocardial
    • Intraprostatic
    • Topical grafting
    • Infusion
  • GLP-compliant necropsy, histology, and histopathology departments
  • Small and large animal in vivo models
  • Bacterial enumeration in tissues and organs
  • Specialized inoculation routes, including intratracheal, nasal, and intramuscular options
  • Frozen bacterial stocks and ATCC availability
  • Antigen-specific responses (titering, isotyping)
  • Phagocytosis assays
  • T helper cell (Th1/Th2) ex vivo analysis
  • Inflammation, cardiovascular, stroke, orthopaedic, wound healing, and other therapeutic area models
  • Immunocompromised rodent handling
  • Immunosuppressed large animal handling in specialized facilities to ensure prolonged animal health
  • Quantitative polymerase chain reaction (qPCR) for biodistribution
  • GLP-validated methods, compliant facilities, and robotics
  • Validated use of immunohistochemical and immunofluorescent staining, immunoassays, and flow cytometry
  • Robotic, fully automated DNA and RNA sample preparation, GLP capable
  • High-throughput flow cytometry, GLP capable
  • Automated, microfluidics-based sizing quantification, and quality control of DNA/RNA, and proteins
  • Protein quantification including protein concentration, ELISA, and western blot analysis
  • Microplate assays for enzyme activities and measurement of biomolecules
  • Quantitative real-time PCR (qPCR) and reverse transcription qPCR (qRT-PCR), GLP capable
  • Board-certified anatomical and clinical pathologists
  • Two board-certified veterinary ophthalmologists
  • Dedicated Study Director, Scientist, and Veterinarian support with 50-plus years of experience

250+

studies conducted in the last 5 years

50+

years of combined experience

10.5

million cases of infectious illness are prevented each year

2.5

million deaths in children are prevented from diphtheria, tetanus, pertussis, and measles each year